Comparative clinical study of the anti-emetic effects of oral ramosetron and injected granisetron in patients with malignant glioma undergoing ACNU chemotherapy

Neurologia Medico-Chirurgica

Volumn 45, Issue 6, 2005, Pages 294-298

  Yano, Shigetoshi ^a,c   Makino, Keishi ^a   Nakamura, Hideo ^a   Kai, Yutaka ^a   Morioka, Motohiro ^a   Hamada, Jun Ichiro ^a   Kochi, Masato ^b   Kuratsu, Jun Ichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b San ai Hospital   (Japan)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti emesis; Chemotherapy; Glioma

Indexed keywords

ANTIEMETIC AGENT; CARMUSTINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GRANISETRON; LOMUSTINE; NIMUSTINE; RAMOSETRON;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER GRADING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG COST; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HUMAN; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VOMITING;

ADULT; AGED; ANOREXIA; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; BRAIN NEOPLASMS; FEMALE; GLIOMA; GRANISETRON; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; VOMITING;

EID: 21744456052     PISSN: 04708105     EISSN: None     Source Type: Journal    
DOI: 10.2176/nmc.45.294     Document Type: Article

References (9)

1. Andrews PL, Bhandari P: The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Eur J Cancer 29A Suppl 1: S11-16, 1993
2. Andrews PL, Davis CJ, Bingham S, Davidson HI, Hawthorn J, Maskell L: The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 68: 325-345, 1990
3. Feng FY, Zhang P, He YJ, Li YH, Zhou MZ, Cheng G, Yamamoto M: Comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea, and anorexia: A single-blind, randomized, crossover study. Current Therapeutic Research 61: 901-909, 2000
4. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG: Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17: 2971-2994, 1999
5. Ito H, Akuzawa S, Tsutsumi R, Kiso T, Kamato T, Nishida A, Yamano M, Miyata K: Comparative study of the affinities of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex. Neuropharmacology 34: 631-637, 1995
6. Kang YK, Park YH, Ryoo BY, Bang YJ, Cho KS, Shin DB, Kim HC, Lee KH, Park YS, Lee KS, Heo DS, Kim SY, Cho EK, Lim HY, Kim WK, Lee JA, Kim TY, Lee JC, Yoon HJ, Kim NK: Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron. J Int Med Res 30: 220-229, 2002
7. Nakajima M, Kamanamaru M, Miura H, Takeshige T, Atsuta Y: [Phase I study of YM060]. Rinsho To Kenkyu 72: 2912-2926, 1995 (Jpn)
8. Noda K, Ikeda M, Yoshida O, Yano S, Taguchi T, Shimoyama T, Nakashima M: Clinical evaluation of Ramosetron injections in the treatment of cisplatin-induced nausea and vomiting. J Int Med Res 30: 211-219, 2002
9. Shimizu T, Saijo N: [Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment]. Nippon Rinsho 61: 937-942, 2003 (Jpn, with Eng abstract)